Selling a hemp or CBD business

What changed for hemp, and when does it take effect?

The fiscal 2026 agriculture appropriations law, P.L. 119-37, enacted 12 November 2025, rewrote the federal definition of hemp. As Dykema summarises, the new definition:

• measures 0.3% on a total THC basis, which counts THCA, not only delta-9 THC;
• excludes cannabinoids that the plant does not naturally produce and those synthesised or manufactured outside the plant, which reaches most delta-8 and similar converted products;
• caps finished hemp-derived cannabinoid products at 0.4 mg of total THC per container.

Products outside the definition are marijuana under the Controlled Substances Act. Industrial hemp for fibre, grain, and seed is carved out. The Congressional Research Service covers the detail in IF13136.

The change was due on 12 November 2026. A continuing resolution, H.R. 6500, passed the Senate 90 to 6 on 8 August and the House 370 to 48 on 1 September, and was signed in early September 2026. It moves most of the change to 11 December 2026. The delay is not uniform: Marijuana Moment reports that cannabinoids not capable of being naturally produced by the plant still lose hemp status on 12 November, and that the White House indicated it would not support further extensions. Bills proposing a regulatory framework instead of a ban have been filed; none has been enacted. Dates can move again, so check before you rely on them. The legal background is in hemp vs marijuana: legal distinction for buyers and intoxicating hemp products: regulatory status.

How will a buyer value a hemp or CBD business now?

On the revenue that remains lawful after the effective date, plus any assets that keep their value regardless. Trailing-year revenue from products that will be outside the definition gets little or no multiple.

What you have	How buyers tend to treat it in late 2026
Isolate or broad-spectrum CBD products at or under 0.4 mg total THC per container	Core value. Valued on earnings like a supplement or consumer brand.
Full-spectrum CBD products over 0.4 mg per container	Needs reformulation. Buyer prices in the cost and the sales risk.
Delta-8, delta-10, HHC, THCP, and other converted or synthetic cannabinoids	Little or no going-concern value after 12 November 2026.
Hemp-derived delta-9 beverages and edibles	Value depends on a legislative fix or a state-licensed channel. Often an earn-out, not cash.
THCA flower	Outside the total-THC definition. Treated as marijuana after the effective date.
Fibre, grain, seed, and processing equipment	Unaffected by the cannabinoid rules. Valued on contracts and asset value.
Brand, customer list, retailer and distributor relationships, e-commerce data	Transferable value if the customers will buy a compliant product.
Inventory of soon-to-be non-compliant goods	A liability, not an asset, if it cannot be sold through before the deadline.

Triage your SKUs before you go to market

Do the buyer’s analysis first.

1. List every SKU with trailing 12-month revenue and gross margin.
2. Record total THC per container from current certificates of analysis, not per serving.
3. Mark each SKU as compliant, fixable by reformulation, or not fixable.
4. Total the three groups. The compliant group is the business you are really selling.
5. Write a dated plan for the rest: reformulate, sell through, or discontinue.
6. Note which states you ship to and any state rules stricter than federal law.

Illustrative example

Illustrative only. A CBD brand has $3.0 million in revenue: $1.2 million from isolate products, $0.8 million from full-spectrum tinctures that can be reformulated, and $1.0 million from delta-9 gummies. If a buyer credits 100% of the first group, 50% of the second, and none of the third, the revenue it will pay for is $1.2m + $0.4m = $1.6 million, not $3.0 million. Overheads sized for $3.0 million then have to be cut in the projections for the earnings to make sense.

Who buys hemp and CBD companies?

Expect strategic buyers more than financial ones: supplement and consumer goods companies, beverage distributors, competitors consolidating, and state-licensed marijuana operators. For intoxicating formulations, the licensed marijuana channel may be the only lawful home after the deadline, which means those assets, such as recipes, brand, and equipment, may interest a licensed manufacturer even though your own company cannot make the transition without a marijuana licence. See manufacturing and extraction businesses.

How a hemp sale differs from a marijuana sale

Issue	Hemp or CBD business	State-licensed marijuana business
Ownership-change approval	Usually none, beyond state hemp or food registrations	Required before closing
Licence transfer	USDA producer licences may not be sold, assigned, or transferred; buyer applies for its own	State-specific transfer or ownership-change process
280E	Does not apply to lawful hemp	Applies to adult-use; see 280E explained
Banking and cards	Available, but processors drop high-risk SKUs quickly	Limited
SBA lending	Possible only with documented product legality	Ineligible; see why SBA and banks are unavailable
Bankruptcy	Generally available if the business is federally lawful	Generally unavailable
Interstate sales	Allowed for lawful hemp, subject to state product laws	Not allowed

The practical result is that a hemp deal can close in weeks once terms are agreed, with no regulator clock.

Deal terms that fit the uncertainty

Buyers will ask you to share the legislative risk. Common tools:

• Asset sale. Buyers avoid inheriting product liability and any exposure from past sales of non-compliant goods. See asset sale vs membership-interest sale.
• Earn-out on at-risk lines. Cash for the compliant business, with contingent payments if intoxicating products remain lawful or a federal framework passes. See earn-outs in cannabis deals.
• Inventory cut-off. Non-compliant inventory excluded, or bought at cost only if sold before the deadline.
• Product reps. Expect detailed representations on testing, labelling, age-gating, and state registrations, and FDA-related claims on marketing.

Sell now or wait?

Your position	Reasonable approach
Mostly compliant revenue	No forced timing. Competitors exiting may improve your numbers in 2027.
Mixed portfolio	Reformulate now and sell on demonstrated compliant revenue, or sell now with an earn-out.
Mostly intoxicating products	Waiting is a wager on Congress. Explore a sale of brand and assets to a licensed operator now, or plan an orderly wind-down; see wind-down vs sale.
Grower or processor of fibre and grain	The cannabinoid rules are largely not your issue. Sell on contracts and equipment.

More on how this licence class is bought and valued is in hemp and CBD businesses. This page is educational, not legal advice, and federal hemp rules are changing quickly.